13 August 2020 in Current Cardiology Reports
6 October 2021 in JACC: Case Reports
We discuss an adolescent with Marfan syndrome and a previous aortic valve-sparing root replacement who was found to have mitral annular disjunction on surveillance cardiac imaging in the setting of recurrent palpitations. Ambulatory heart rate monitoring incidentally captured a fatal ventricular arrhythmia, a well-recognized but underappreciated cause of sudden cardiac death in patients with Marfan syndrome. (Level of Difficulty: Advanced.)
12 August 2025 in Journal of the American Heart Association
Background: In the FUEL (Fontan Udenafil Exercise Longitudinal) trial, a positive treatment effect was identified for outcomes at the ventilatory anaerobic threshold but not for the primary outcome, oxygen consumption (V o 2 ) at peak exercise. This disparate response may be explained by the physiologic challenge of improving peak V o 2 in participants with near‐normal baseline exercise performance. Methods: Participants were divided into subgroups by baseline predicted peak V o 2 (<80% versus ≥80%). Treatment effect was evaluated in those with a baseline peak V o 2 <80% predicted and linear regression was performed to examine the interaction between subgroup and response to therapy for the primary and secondary outcomes. Results: Of the 379 participants with paired exercise data, 302 (80%) had a baseline peak V o 2 <80% predicted. In this subgroup, the primary outcome of peak V o 2 improved significantly after 6 months of udenafil treatment, when compared with placebo (0.23±4.17 mL/kg per min versus −0.90±3.74 mL/kg per min; P =0.021). Secondary outcome measures, including V o 2 at ventilatory anaerobic threshold ( P =0.023), work at ventilatory anaerobic threshold ( P =0.032), and the myocardial performance index ( P =0.007) were all significantly improved as well. A significant interaction was found between exercise subgroups and response to udenafil for peak V o 2 ( P =0.036) but not for other outcomes. Conclusions: In this post hoc subgroup analysis, after exclusion of patients with Fontan circulation with near‐normal baseline peak V o 2 , a positive treatment effect of udenafil was identified for the primary outcome of peak V o 2 . The interaction between baseline peak V o 2 and treatment may have influenced the outcome of the FUEL trial. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT0274115.
7 August 2014 in Pediatric Cardiology
Cardiac magnetic resonance imaging (CMRI) is increasingly utilized in the management of patients with congenital heart disease. Unfortunately, the expertise to perform and interpret these studies is not universally available, despite an increasing population of congenital heart survivors. This retrospective analysis describes our experience providing on-site CMRI services compared with providing the same services over a geographic distance of 250 miles. There were 83 local scans with both physician and patient on-site compared with 91 scans controlled by a physician geographically remote from the patients. The patients were well-matched for age, sex, study duration, scan type, and history of prior cardiac intervention. There was no difference in use of deep sedation or diazepam for anxiolysis, or use of atropine for arrhythmia suppression. There were no patient safety issues and there was satisfaction on the part of the referring physicians who were able to obtain more timely studies, as well as the remote-scanning physicians who had a workflow comparable with the local scans, but no lost travel time. This experience suggests that remote delivery of cardiac MRI services for the congenital heart population is feasible and can be done with comparable success and safety to a traditional “local” model. We also suggest the configuration to provide such remote CMRI services with commercially available hardware and software.
12 September 2024 in Journal of Cardiovascular Magnetic Resonance
Cardiovascular magnetic resonance (CMR) is used to diagnose myocarditis in adults and children based on the original Lake Louise criteria (LLC) and more recently the revised LLC. The major change included in the revised LLC was the incorporation of parametric mapping, which significantly increases the sensitivity and specificity of diagnosis. Subsequently, scientific statements have recommended the use of parametric mapping in the diagnosis of myocarditis in children. However, there are some challenges to parametric mapping that are unique to the pediatric population. Our goal is to characterize clinical CMR and parametric mapping practice patterns for the diagnosis of myocarditis in pediatric centers. The Cardiovascular Magnetic Resonance Evaluation in Return to Athletes for Myocarditis in Coronavirus Disease 2019 and Immunization Consortium (CERAMICi) created a Research Electronic Data Capture (REDCap) survey to evaluate clinical practice patterns for diagnosis of myocarditis in pediatrics. This survey was distributed to the Society for Cardiovascular Magnetic Resonance community. Fifty-nine responses from 51 centers were received, with only one response from each center being utilized. Only 35% (18/51) of centers (37% (14/38) North America, 31% (4/13) international) reported using CMR routinely in all patients with a suspicion of myocarditis. Diagnostic uncertainty was noted as the most important reason for CMR, while cost was noted as the least important consideration. The majority of centers reported using the revised LLC (37/51, 72%) compared to original LLC (7/51, 14%) or a hybrid criteria (6/51, 12%). When looking at the use of parametric mapping, only 5/47 (11%) for T1 mapping and 11/49 (22%) for T2 mapping reported having scanner-specific pediatric normative data. Routine CMR imaging for diagnosis of myocarditis in pediatrics is infrequently performed at surveyed centers despite the focus on a group of non-invasive cardiac imagers. While the majority reported using parametric mapping, few centers reported having pediatric scanner-specific normative data. This highlights an important gap in the utilization of CMR that may aid in the diagnosis of myocardial disease.